MONDAY.COM
24.5.2022 08:02:14 CEST | Business Wire | Press release
monday.com (NASDAQ: MNDY), a work operating system (Work OS) where organisations of any size can create the tools and processes they need to manage every aspect of their work, has opened a new, larger office in London as it continues to expand in the UK and globally. As monday.com’s European headquarters, the new office can hold up to 150 people and is located in Fitzrovia, one of the main epicentres of London’s bustling tech scene.
This new premises comes soon after the launch of monday.com’s first UK office, which had only opened in November 2021. The company has scaled significantly in the past five months, prompting the move to a bigger space much sooner than initially anticipated: not only did monday.com double its headcount last year, the company is planning to have more than 100 employees in the UK by the end of 2022, and is currently hiring for open roles across IT, consulting, marketing, and partnerships and alliances. monday.com has also chosen the London office as the first international location for its training academy, monday U . An academic initiative, monday U will train talented individuals looking to enter the tech industry so they can access roles at monday.com and the UK high-tech industry at large.
“We are so proud to launch our new home in London’s bustling tech community, which will act as our EMEA headquarters. Designed to reflect our values , it is a space for monday.com employees, customers, and partners to collaborate as colleagues and friends”, says Naveed Malik, Regional Director, EMEA at monday.com. “We are rapidly expanding our customer and partner ecosystem as well, and are thrilled to see more and more companies grow with us, leveraging agile low-code and no-code solutions to manage their work”.
Similar to its offices in other locations, such as New York City and Tel Aviv, this new space not only reflects monday.com’s core values, including collaboration, ownership, and transparency, but also empowers people to live them in their day-to-day work. For example, transparency is reflected through digital dashboards on the walls where teams can showcase the data they are using to progress projects. Similarly, a sense of collaboration is encouraged through thoughtful seating plans across the office, ranging from informal sofa corners to meeting rooms of various sizes that can accommodate all team types.
“The collaboration between our workplace design team and the local employees, as they shared thoughts and got live feedback throughout the process was incredible. Everyone in the London office had the opportunity to feel part of the company in a tangible way that goes beyond day-to-day work,” explains Keren Reznik, workplace design team lead at monday.com. “This will be an ongoing process – our space will evolve to reflect our culture and the changing tech industry. We are already looking at possible concept options for our second floor, which will open in July.”
To learn more about monday.com’s growth, please go here to read its latest earnings report. To view or apply for any of the open roles in the UK, please visit the company’s careers page .
About monday.com
The monday.com Work OS is an open platform that democratises the power of software so organisations can easily build work management tools and software applications to fit their every need. The platform intuitively connects people to processes and systems, empowering teams to excel in every aspect of their work while creating an environment of transparency in business. monday.com has teams in Tel Aviv, New York, San Francisco, Miami, Chicago, London, Kiev, Sydney, São Paulo, and Tokyo. The platform is fully customizable to suit any business vertical and is currently used by over 152,000 customers across over 200 industries in 200 countries.
Visit us on our LinkedIn , Twitter , Instagram , YouTube , TikTok and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005834/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
